	US 12,264,326 B2
	Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
J. Keith Joung, Winchester, MA (US); and Peter Cabeceiras, Boston, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Jul. 13, 2023, as Appl. No. 18/351,689.
Application 18/351,689 is a continuation of application No. 17/617,490, previously published as PCT/US2020/037740, filed on Jun. 15, 2020.
Claims priority of provisional application 62/861,186, filed on Jun. 13, 2019.
Prior Publication US 2024/0011050 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01)

CPC C12N 15/86 (2013.01) [C07K 14/005 (2013.01); C12N 2740/10023 (2013.01); C12N 2740/10042 (2013.01); C12N 2740/10052 (2013.01)]

27 Claims

1. A method of engineering a target cell, the method comprising contacting a particle to the target cell, wherein the particle comprises:

(a) a phospholipid bilayer membrane comprising a human endogenous retrovirus (HERV) glycoprotein;

(b) a HERV GAG protein encapsulated within the phospholipid bilayer membrane; and

(c) a therapeutic cargo encapsulated within the phospholipid bilayer membrane, wherein the therapeutic cargo is fused with a plasma membrane recruitment domain, wherein the plasma membrane recruitment domain is not a viral GAG protein or a CD63 protein.